Forecast to Publish a Notice of Funding Opportunity for The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratory (U24 Clinical Trial Not Allowed)
The NCI will fund institutions to run a laboratory supporting early-phase cancer drug trials by providing pharmacokinetic analyses, biospecimen management, and scientific leadership for the ETCTN network.
Funder: National Institutes of Health
Due Dates: June 30, 2026 (Full application deadline) | June 30, 2026 (Original closing date)
Funding Amounts: Estimated total program funding: $850,000; 1 award expected; duration not specified.
Summary: Supports the establishment or maintenance of a Pharmacokinetics Resource Laboratory to advance clinical development of NCI IND agents within the Experimental Therapeutics Clinical Trials Network.
Description
This funding opportunity, issued by the National Cancer Institute (NCI) of the NIH, seeks applications from institutions or organizations to establish or maintain a Pharmacokinetics Resource Laboratory (PK Laboratory) for the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratory will organize biospecimen collections and conduct analyses related to pharmacokinetic endpoints, drug-drug interactions, CYP interactions, pharmacodynamics, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The primary goal is to support early phase clinical trials and translational research by providing a comprehensive understanding of pharmacokinetic behavior for agents under study, thereby advancing their clinical development. The initiative encourages multidisciplinary teams with expertise in clinical pharmacology, early drug development, and translational research.
